Viking Therapeutics to Attend Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy VKTX?
Source: PRnewswire
- Clinical Stage Progress: Viking Therapeutics is advancing its VK2735 in a Phase 3 obesity program, which includes the VANQUISH-1 and VANQUISH-2 trials, aimed at evaluating its potential in treating metabolic disorders, with preliminary data indicating good safety and tolerability, potentially establishing a competitive edge for the company in the market.
- New Drug Development Success: VK2809 achieved both primary and secondary endpoints in a Phase 2b study for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis, demonstrating effectiveness that could open new market opportunities for the company in lipid and metabolic disease treatment.
- Innovative Treatment Solutions: Viking is developing a series of dual amylin and calcitonin receptor agonists (DACRAs) to address obesity and other metabolic disorders, showcasing the company's ongoing commitment to innovative drug development and strategic positioning in the market.
- Rare Disease Research: VK0214 showed good safety and tolerability in a Phase 1b clinical trial for X-linked adrenoleukodystrophy (X-ALD), significantly reducing plasma levels of very long-chain fatty acids, potentially providing new solutions for rare disease treatment and enhancing the company's R&D capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.950
Low
70.00
Averages
97.00
High
125.00
Current: 34.950
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics to Attend Multiple Investor Conferences
- Investor Conference Schedule: Viking Therapeutics will participate in investor conferences on April 14 and April 16, 2026, in New York and Boston respectively, where management will hold one-on-one meetings aimed at attracting potential investors and enhancing company visibility.
- Clinical Trial Progress: Viking's VK2735 is undergoing Phase 3 trials for obesity, including VANQUISH-1 and VANQUISH-2, with early trials demonstrating a favorable safety and tolerability profile, potentially laying a foundation for the company's future market performance.
- New Drug Development Updates: VK2809 has successfully met both primary and secondary endpoints in Phase 2 trials for non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, showing significant reductions in LDL-C and liver fat content, thereby enhancing the company's competitiveness in the metabolic disease sector.
- Rare Disease Research: Viking is developing VK0214 for the treatment of X-ALD, with preliminary trial results indicating good safety and significant reductions in plasma levels of very long-chain fatty acids, showcasing the company's potential in the rare disease space.
See More
Viking Therapeutics to Attend Investor Conferences
- Clinical Stage Progress: Viking Therapeutics is advancing its VK2735 in a Phase 3 obesity program, which includes the VANQUISH-1 and VANQUISH-2 trials, aimed at evaluating its potential in treating metabolic disorders, with preliminary data indicating good safety and tolerability, potentially establishing a competitive edge for the company in the market.
- New Drug Development Success: VK2809 achieved both primary and secondary endpoints in a Phase 2b study for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis, demonstrating effectiveness that could open new market opportunities for the company in lipid and metabolic disease treatment.
- Innovative Treatment Solutions: Viking is developing a series of dual amylin and calcitonin receptor agonists (DACRAs) to address obesity and other metabolic disorders, showcasing the company's ongoing commitment to innovative drug development and strategic positioning in the market.
- Rare Disease Research: VK0214 showed good safety and tolerability in a Phase 1b clinical trial for X-linked adrenoleukodystrophy (X-ALD), significantly reducing plasma levels of very long-chain fatty acids, potentially providing new solutions for rare disease treatment and enhancing the company's R&D capabilities.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Healthcare Stocks Performance in Economic Recession
- Defensive Healthcare Advantage: Large-cap healthcare stocks like Johnson & Johnson and CVS Health exhibit strong performance during economic downturns, with low beta values (0.33 for JNJ and 0.46 for CVS) indicating smaller losses during market declines, thus providing a stable income source for risk-averse investors.
- Rising Recession Risks: The ongoing conflict in Iran has led to soaring energy and food prices, increasing the risk of a global economic recession, prompting investors to gravitate towards healthcare stocks to mitigate potential market volatility and uncertainty.
- High-Risk, High-Reward Strategy: Smaller healthcare companies such as Grail and Viking Therapeutics present high-risk, high-reward investment opportunities; despite Grail's multi-cancer early detection test failing to meet primary endpoints, follow-up data could potentially shift market perceptions positively.
- Portfolio Diversification: In light of increasing economic uncertainty, building a diversified portfolio of small healthcare companies can effectively mitigate stock-specific risks, particularly those reliant on clinical trial outcomes, which may offer potential returns amidst market fluctuations.
See More
Iran Conflict Raises Recession Risks Amid Inflation
- Recession Risk: The ongoing conflict in Iran is causing inflationary pressures from soaring energy and food prices, complicating global economic challenges and increasing investor interest in healthcare stocks as a defensive measure.
- Defensive Healthcare Stocks: Large-cap pharmaceutical company Johnson & Johnson (JNJ) and integrated healthcare company CVS Health are viewed as defensive stocks, with JNJ's beta at 0.33 and CVS at 0.46, indicating their relative stability during economic downturns.
- Opportunities in Small-Cap Stocks: Investors may consider small- and mid-cap healthcare companies whose growth relies on binary events like clinical trial results, as successful firms can offset losses from others, despite the inherent risks.
- Investment Strategy Choices: Risk-averse investors may prefer low-beta defensive stocks, while risk-seeking investors might opt for high-risk, high-reward healthcare stocks to navigate potential recessionary pressures.
See More
Viking Therapeutics Faces Challenges in Weight Loss Market
- Clinical Trial Progress: Viking Therapeutics' leading candidate VK2735 is undergoing pivotal 78-week phase 3 studies, with the second study recently completing enrollment; strong results could establish a solid foundation for the company in the competitive weight-loss market.
- Significant Market Potential: Analysts predict VK2735 could generate peak sales of $14.4 billion in the U.S. and $7.2 billion in Europe, totaling $21.6 billion, highlighting the drug's market potential as the weight-loss sector is projected to exceed $100 billion in the next decade.
- Increasing Competitive Pressure: While VK2735 aims to match the efficacy of Eli Lilly's Zepbound, Viking Therapeutics must demonstrate exceptional results in clinical trials to secure its position in the weight-loss drug market as competition intensifies.
- Investment Risk Advisory: Viking Therapeutics faces clinical, regulatory, competitive, and funding challenges, and while its stock may soar over the next decade, the risk of bankruptcy remains, necessitating cautious consideration from investors.
See More
Viking Therapeutics to Attend Multiple Investor Conferences
- Investor Conference Schedule: Viking Therapeutics will participate in investor conferences on April 14 and April 16, 2026, in New York and Boston respectively, where management will hold one-on-one meetings aimed at attracting potential investors and enhancing company visibility.
- Clinical Trial Progress: Viking's VK2735 is undergoing Phase 3 trials for obesity, including VANQUISH-1 and VANQUISH-2, with early trials demonstrating a favorable safety and tolerability profile, potentially laying a foundation for the company's future market performance.
- New Drug Development Updates: VK2809 has successfully met both primary and secondary endpoints in Phase 2 trials for non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, showing significant reductions in LDL-C and liver fat content, thereby enhancing the company's competitiveness in the metabolic disease sector.
- Rare Disease Research: Viking is developing VK0214 for the treatment of X-ALD, with preliminary trial results indicating good safety and significant reductions in plasma levels of very long-chain fatty acids, showcasing the company's potential in the rare disease space.
See More
Viking Therapeutics to Attend Investor Conferences
- Clinical Stage Progress: Viking Therapeutics is advancing its VK2735 in a Phase 3 obesity program, which includes the VANQUISH-1 and VANQUISH-2 trials, aimed at evaluating its potential in treating metabolic disorders, with preliminary data indicating good safety and tolerability, potentially establishing a competitive edge for the company in the market.
- New Drug Development Success: VK2809 achieved both primary and secondary endpoints in a Phase 2b study for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis, demonstrating effectiveness that could open new market opportunities for the company in lipid and metabolic disease treatment.
- Innovative Treatment Solutions: Viking is developing a series of dual amylin and calcitonin receptor agonists (DACRAs) to address obesity and other metabolic disorders, showcasing the company's ongoing commitment to innovative drug development and strategic positioning in the market.
- Rare Disease Research: VK0214 showed good safety and tolerability in a Phase 1b clinical trial for X-linked adrenoleukodystrophy (X-ALD), significantly reducing plasma levels of very long-chain fatty acids, potentially providing new solutions for rare disease treatment and enhancing the company's R&D capabilities.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Healthcare Stocks Performance in Economic Recession
- Defensive Healthcare Advantage: Large-cap healthcare stocks like Johnson & Johnson and CVS Health exhibit strong performance during economic downturns, with low beta values (0.33 for JNJ and 0.46 for CVS) indicating smaller losses during market declines, thus providing a stable income source for risk-averse investors.
- Rising Recession Risks: The ongoing conflict in Iran has led to soaring energy and food prices, increasing the risk of a global economic recession, prompting investors to gravitate towards healthcare stocks to mitigate potential market volatility and uncertainty.
- High-Risk, High-Reward Strategy: Smaller healthcare companies such as Grail and Viking Therapeutics present high-risk, high-reward investment opportunities; despite Grail's multi-cancer early detection test failing to meet primary endpoints, follow-up data could potentially shift market perceptions positively.
- Portfolio Diversification: In light of increasing economic uncertainty, building a diversified portfolio of small healthcare companies can effectively mitigate stock-specific risks, particularly those reliant on clinical trial outcomes, which may offer potential returns amidst market fluctuations.
See More
Iran Conflict Raises Recession Risks Amid Inflation
- Recession Risk: The ongoing conflict in Iran is causing inflationary pressures from soaring energy and food prices, complicating global economic challenges and increasing investor interest in healthcare stocks as a defensive measure.
- Defensive Healthcare Stocks: Large-cap pharmaceutical company Johnson & Johnson (JNJ) and integrated healthcare company CVS Health are viewed as defensive stocks, with JNJ's beta at 0.33 and CVS at 0.46, indicating their relative stability during economic downturns.
- Opportunities in Small-Cap Stocks: Investors may consider small- and mid-cap healthcare companies whose growth relies on binary events like clinical trial results, as successful firms can offset losses from others, despite the inherent risks.
- Investment Strategy Choices: Risk-averse investors may prefer low-beta defensive stocks, while risk-seeking investors might opt for high-risk, high-reward healthcare stocks to navigate potential recessionary pressures.
See More
Viking Therapeutics Faces Challenges in Weight Loss Market
- Clinical Trial Progress: Viking Therapeutics' leading candidate VK2735 is undergoing pivotal 78-week phase 3 studies, with the second study recently completing enrollment; strong results could establish a solid foundation for the company in the competitive weight-loss market.
- Significant Market Potential: Analysts predict VK2735 could generate peak sales of $14.4 billion in the U.S. and $7.2 billion in Europe, totaling $21.6 billion, highlighting the drug's market potential as the weight-loss sector is projected to exceed $100 billion in the next decade.
- Increasing Competitive Pressure: While VK2735 aims to match the efficacy of Eli Lilly's Zepbound, Viking Therapeutics must demonstrate exceptional results in clinical trials to secure its position in the weight-loss drug market as competition intensifies.
- Investment Risk Advisory: Viking Therapeutics faces clinical, regulatory, competitive, and funding challenges, and while its stock may soar over the next decade, the risk of bankruptcy remains, necessitating cautious consideration from investors.
See More
